Clinical Trials

982 enrolled 15 charts

Prostatic Neoplasms

NCT04338269 2026-03-19

CONTACT-03

Phase 3 Terminated

522 enrolled 22 charts

Carcinoma, Renal Cell

NCT01575548 2026-03-18

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

129 enrolled 11 charts

Carcinoma, Renal Cell

NCT03055013 2026-03-17

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

819 enrolled 12 charts

Carcinoma, Renal Cell

NCT03274687 2026-03-16

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

296 enrolled 29 charts

Prostate Adenocarcinoma

NCT03748641 2026-03-16

MAGNITUDE

765 enrolled 16 charts 1 FDA

Prostatic Neoplasms, Castration-Resistant

NCT03732677 2026-03-13

NIAGARA

1,063 enrolled 15 charts 1 FDA

Urinary Bladder Neoplasms

NCT05171816 2026-03-11

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

110 enrolled 12 charts

Metastatic Castration-resistant Prostate Cancer

NCT03142334 2026-03-10

KEYNOTE-564

994 enrolled 10 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT00936390 2026-03-06

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

1,538 enrolled 37 charts

Prostatic Neoplasms

NCT01546987 2026-03-06

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

239 enrolled 38 charts

Prostatic Neoplasms

NCT03036098 2026-03-06

CheckMate901

1,314 enrolled 23 charts 1 FDA

Urothelial Cancer

NCT00063882 2026-03-05

Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

588 enrolled 34 charts

Prostatic Neoplasms

NCT04736199 2026-02-27

ARANOTE

669 enrolled 16 charts

Prostatic Neoplasms

NCT00699751 2026-02-23

ALSYMPCA

921 enrolled 43 charts

Hormone Refractory Prostate Cancer

NCT02811861 2026-02-23

CLEAR

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell

NCT04689828 2026-02-20

PSMAfore

469 enrolled 11 charts 1 FDA

Prostatic Neoplasms

NCT04497844 2026-02-13

AMPLITUDE

696 enrolled 15 charts 1 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT04076059 2026-02-06

China ARCHES

180 enrolled 24 charts

Metastatic Hormone Sensitive Prostate Cancer

NCT03898180 2026-02-05

LEAP-011

505 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT01946204 2026-02-02

SPARTAN

1,207 enrolled 15 charts 1 FDA

Prostatic Neoplasms

NCT02489318 2026-02-02

TITAN

1,052 enrolled 13 charts 1 FDA

Prostatic Neoplasms

NCT02853331 2026-02-02

KEYNOTE-426

861 enrolled 24 charts 1 FDA

Carcinoma, Renal Cell

NCT03390504 2026-02-02

THOR

629 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Urothelial Cancer

NCT02003924 2026-01-27

PROSPER

1,401 enrolled 25 charts 1 FDA

Prostatic Neoplasms

NCT03091192 2026-01-23

Savolitinib vs. Sunitinib in MET-driven PRCC.

60 enrolled 15 charts

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT04165317 2026-01-22

CREST

1,068 enrolled 20 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04647526 2026-01-13

SPLASH

455 enrolled 18 charts

Prostatic Neoplasms

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

608 enrolled 22 charts 1 FDA

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT01809691 2025-12-31

S1216

1,313 enrolled 22 charts

Prostatic Neoplasms

NCT04446117 2025-12-18

CONTACT-02

575 enrolled 13 charts

Prostatic Neoplasms

NCT00309985 2025-12-11

CHAARTED

790 enrolled 11 charts

Metastatic Hormone-sensitive Prostate Cancer

NCT02677896 2025-10-24

ARCHES

1,150 enrolled 23 charts 1 FDA

Metastatic Hormone Sensitive Prostate Cancer

NCT04838613 2025-10-20

GuidePath

190 enrolled 25 charts

Prostatic Neoplasms, Recurrence

NCT04186845 2025-09-22

Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence

391 enrolled 30 charts

Disease, Prostatic Neoplasms

NCT01120249 2025-09-16

S0931

1,545 enrolled 15 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04149574 2025-09-16

CheckMate 7G8

Phase 3 Terminated

13 enrolled 11 charts

Urinary Bladder Neoplasms

NCT03937219 2025-09-10

COSMIC-313

855 enrolled 12 charts

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT05590793 2025-09-09

Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

195 enrolled 19 charts

Prostatic Neoplasms

NCT03374488 2025-08-22

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

84 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT02684006 2025-07-30

JAVELIN Renal 101

886 enrolled 37 charts 1 FDA

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT03260894 2025-07-29

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

129 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT03834493 2025-07-18

KEYNOTE-641

1,244 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT03834506 2025-07-18

KEYNOTE-921

1,030 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT05547386 2025-07-18

68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer

163 enrolled 3 charts

Prostatic Neoplasms

NCT02319837 2025-07-08

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

1,068 enrolled 20 charts 1 FDA

Prostatic Neoplasms

NCT05288166 2025-06-27

CYCLONE 3

925 enrolled 12 charts

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

NCT02231749 2025-06-26

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

1,390 enrolled 18 charts 1 FDA

Carcinoma, Renal Cell

NCT04223856 2025-06-13

EV-302

886 enrolled 12 charts 1 FDA